In conclusion, our study for the first time confirmed apatinib’s anti-tumor effect through PI3K/Akt/GSK signaling pathway in vitro and in vivo, enriching the anti-tumor mechanism of targeted drug apatinib. Here, AKT1 is linked to neoplasm.